Alexander I. Spira, MD, PhD, FACP, discusses additional studies investigating the use of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.
Alexander I. Spira, MD, PhD, FACP, research institute director, Thoracic and Phase 1 Trial Program, Virginia Cancer Specialists Research Institute, Virginia Cancer Specialists, clinical assistant professor, Johns Hopkins University, discusses additional studies investigating the use of lazertinib (Leclaza) and amivantamab-vmjw (Rybrevant) in EGFR-mutated non–small cell lung cancer (NSCLC).
The combination of lazertinib and amivantamab could have a role in several indications for patients with EGFR-mutated NSCLC, such as the in the treatment-naïve setting or the refractory setting, Spira says. The two agents could also be evaluated in combination with chemotherapy before or after treatment with osimertinib (Tagrisso), and they could potentially replace osimertinib, Spira notes.
The phase 3 MARIPOSA-2 trial (NCT04988295) is investigating the combination of lazertinib and amivantamab plus chemotherapy vs chemotherapy alone for patients with EGFR-mutated, locally advanced or metastatic NSCLC who failed treatment on osimertinib. Amivantamab plus chemotherapy is also being compared with chemotherapy alone as a frontline treatment for patients with advanced or metastatic NSCLC harboring EGFR exon 20 insertions in the phase 3 PAPILLON trial (NCT04538664).
Since lazertinib/amivantamab has demonstrated the ability to overcomeosimertinib resistance, investigators want to continue exploring optimal settings for the combination’s use, Spira continues. An additional area of exploration could come in the adjuvant setting, Spira concludes.